These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25108647)

  • 21. Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study.
    Bagaphou TC; Cerotto V; Gori F
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):14-20. PubMed ID: 31755078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists.
    Strick V
    Curr Med Res Opin; 2014 Oct; 30(10):2085-92. PubMed ID: 24983745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tapentadol Prolonged Release for Severe Chronic Osteoarthritis Pain in the Elderly-A Subgroup Analysis of Routine Clinical Practice Data.
    Schwittay A; Sohns M; Heckes B; Elling C
    Pain Res Manag; 2020; 2020():5759265. PubMed ID: 32351639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tapentadol prolonged release in association with analgesic radiofrequency for the treatment of chronic lumbar radicular pain: an observational, prospective study.
    Visconti C; Mastroluca A; Varano L; Del Gaudio A
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):27-34. PubMed ID: 31755082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tapentadol Prolonged Release: A Review in Pain Management.
    Deeks ED
    Drugs; 2018 Nov; 78(17):1805-1816. PubMed ID: 30471002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tapentadol: an analgesic that differs from classic opioids due to its noradrenergic mechanism of action.
    Caputi FF; Nicora M; Simeone R; Candeletti S; Romualdi P
    Minerva Med; 2019 Feb; 110(1):62-78. PubMed ID: 30667206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.
    Hartrick CT; Rozek RJ
    CNS Drugs; 2011 May; 25(5):359-70. PubMed ID: 21476608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique pharmacology of tapentadol for treating acute and chronic pain.
    Knezevic NN; Tverdohleb T; Knezevic I; Candido KD
    Expert Opin Drug Metab Toxicol; 2015; 11(9):1475-92. PubMed ID: 26215077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tapentadol versus classical WHO-III opioids for chronic back pain. Health services research study based on representative data from health insurance funds].
    Kern KU; Vogelmann T; Tölle TR
    MMW Fortschr Med; 2022 Apr; 164(Suppl 6):19-27. PubMed ID: 35449488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical practice data regarding tapentadol prolonged release treatment for severe chronic pain - improvement of analgesia, functional competence and quality of life in particular under tapentadol monotherapy].
    Lange T; Krings D; Waldmann-Rex S
    MMW Fortschr Med; 2015 Apr; 157(157 Suppl 4):12-21. PubMed ID: 26013114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term, prolonged-release oral tapentadol for the treatment of refractory chronic low back pain: a single-center, observational study.
    Finco G; Mura P; Musu M; Deidda C; Saba M; Demelas I; Evangelista M; Sardo S
    Minerva Med; 2018 Aug; 109(4):259-265. PubMed ID: 29947490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of tapentadol prolonged release during rehabilitation: a prospective, observational study.
    Orfei M; Milia P; Caserio M; Bagaphou TC
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):21-26. PubMed ID: 31755077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
    Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
    Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy.
    Niesters M; Proto PL; Aarts L; Sarton EY; Drewes AM; Dahan A
    Br J Anaesth; 2014 Jul; 113(1):148-56. PubMed ID: 24713310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and tolerability of tapentadol sustained release in the Australian setting.
    Russo MA; Santarelli DM
    J Opioid Manag; 2016; 12(3):187-96. PubMed ID: 27435439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine.
    Ikenberg R; Hertel N; Moore RA; Obradovic M; Baxter G; Conway P; Liedgens H
    J Med Econ; 2012; 15(4):724-36. PubMed ID: 22364286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
    Merchant S; Noe LL; Howe A; Duff S; Gricar J; Ogden K; Mody SH
    Clin Ther; 2013 May; 35(5):659-72. PubMed ID: 23587608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient-relevant outcomes and health-related quality of life in patients with chronic, severe, noncancer pain treated with tapentadol prolonged release-Using criteria of health technology assessment.
    Hofmann JF; Lal A; Steffens M; Boettger R
    J Opioid Manag; 2016; 12(5):323-331. PubMed ID: 27844472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain.
    Wild JE; Grond S; Kuperwasser B; Gilbert J; McCann B; Lange B; Steup A; Häufel T; Etropolski MS; Rauschkolb C; Lange R
    Pain Pract; 2010; 10(5):416-27. PubMed ID: 20602712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.